Navigation Links
Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203
Date:6/18/2009

oduct development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma.

Microme
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ORNL finding could help electronics industry enter new phase
2. Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study
3. FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer
4. InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
5. Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia
6. Medifocus, Inc. receives Authorization Approval from Health Canada to launch its pivotal Phase III clinical study of focused microwave heating for treatment of breast cancer in Canada
7. Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study
8. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
9. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
10. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
11. Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Padre Murphy's and ... supporter of Pro Player Health Alliance (PPHA). The ... Murphy's in getting everyone, including NFL greats, treated for obstructive ... the leading groups supporting the cause in the valley. The ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... An autoimmune inflammatory disease that takes a progressive toll ... the joints, rheumatoid arthritis (RA) is associated with a ... is well known. Less is known about whether ... few decades of remarkable improvements in longevity in the ...
... bone loss caused by hormone and radiation therapies used ... the potential risk of bone fractures and improving quality ... presented on October 28, 2007, at the American Society ... Los Angeles. , Prostate cancer patients are not routinely ...
... 28 Disparities in access to health care ... from receiving needed cancer services and often lead ... impact of cancer education geared toward African-Americans, researchers ... in partnership with The Centers for Healthy Hearts ...
... Looking Younger at American Society of ... Plastic Surgeons Annual Meeting, BALTIMORE, Oct. 28 ... comes to looking younger. In fact,plastic surgeons analyze facial features and ... is in, say,presenters today at the American Society of Plastic Surgeons ...
... Ground Rules for Union Election Say Hospital System Fails ... to ... Hundreds of faith leaders,elected officials and other community members joined healthcare ... outside the,system,s headquarters on Saturday, where they called for hospital,leadership to ...
... Society of Plastic Surgeons Annual ... ... non- and minimally-invasive techniques to,remove fat are making headlines. But are these ... will discuss if,these are cutting edge new discoveries or just "buyer beware" ...
Cached Medicine News:Health News:The widening mortality gap between people with rheumatoid arthritis and the general population 2Health News:The widening mortality gap between people with rheumatoid arthritis and the general population 3Health News:Walking prevents bone loss caused from prostate cancer treatment 2Health News:Education program leads to lasting improvement of cancer knowledge in African Americans 2Health News:Facelift, Botox, or Both? Depends Upon Your Decade of Life 2Health News:Facelift, Botox, or Both? Depends Upon Your Decade of Life 3Health News:Healthcare Workers to St. Joseph Health System: Fair Election Agreement Now 2Health News:Non-Invasive Fat-Melting Procedures - Hype or Reality? 2
(Date:1/23/2015)... Jan. 23, 2015  Today the U.S. Food and Drug ... the prevention of serogroup B meningococcal disease ... vaccine Trumenba®, which received FDA approval in October, represent ... disease. "I have heard over and ...
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease ... health care leaders and a new study analyzing the impact ... PFCD is a nationwide coalition working to educate policy makers and ... at the Capitol was focused on how the Iowa ...
(Date:1/23/2015)... 23, 2015 More than a third of reproductive-aged women ... with private insurance, filled a prescription for an opioid pain ... this week,s Morbidity and Mortality Weekly Report (MMWR). ... treat moderate to severe pain.  They are also found in ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... hold its annual meeting of stockholders on Wednesday, June 9, 2010 at 9:00a.m. Pacific Time for all stockholders of record on ... ... , , ... ...
... the Barclays 2010 Global Healthcare Conference on March 23, 2010 at 1:30 p.m. eastern at the Loews Hotel in Miami, Florida . , ... , ... ... ...
Cached Medicine Technology:PDL BioPharma To Hold Annual Meeting of Stockholders on June 9, 2010 2Express Scripts to Present at Barclays 2010 Global Healthcare Conference 2
... Multi Color (HMC) Anomaloscope ... microprocessor-controlled precision assessment of ... red/green range (Rayleigh equation) ... equation) with integrated automatic ...
... VersaSuite practice management software is ... the business and clinical aspects of ... solution offers support for the financial, ... the eye care professional. Designed as ...
... movement in our country to provide greater ... fact, recent government regulations require it. The ... affords your wheelchair-bound patients easy and comfortable ... having to leave their wheelchair. , ,The ...
... lamp is designed to for use ... slit lamp offers the popular horizontal ... addition to the ReSeeVit family of ... products on the market to capture ...
Medicine Products: